At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Neuroprotectants; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 08 Mar 2000 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Anxiety disorders in USA (Unknown route)